Similar articles

• [Treatment of hepatitis C virus-related cirrhosis].

  Bronowicki JP. Bronowicki JP. Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B220-4. Gastroenterol Clin Biol. 2002. PMID: 12180292 Review. French. No abstract available.
• [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].

  Nishiguchi S, Kubo S, Shiomi S. Nishiguchi S, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):600-4. Nihon Rinsho. 2004. PMID: 15359868 Review. Japanese. No abstract available.
• Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.

  Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N. Imai Y, et al. J Viral Hepat. 2010 Mar;17(3):185-91. doi: 10.1111/j.1365-2893.2009.01163.x. Epub 2009 Aug 26. J Viral Hepat. 2010. PMID: 19709362
• Development of hepatocellular carcinoma after sustained response to interferon therapy: how long should sustained responders with risk factors be followed?

  Kasahara A. Kasahara A. J Gastroenterol. 2005 Feb;40(2):220-2. doi: 10.1007/s00535-005-1545-8. J Gastroenterol. 2005. PMID: 15770412 No abstract available.
• Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.

  Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, Kaneko M, Goto I, Tanaka N, Arakawa Y. Moriyama M, et al. Liver Int. 2005 Feb;25(1):85-90. doi: 10.1111/j.1478-3231.2005.01028.x. Liver Int. 2005. PMID: 15698403